Looking Beyond Its Borders, Russia's Pharmsynthez Plans IPO
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately held firm hopes to raise about £10.5 million to bring two experimental drugs to the U.S. and EU markets.